Vertex: Positive Day 90 Data for 1st Patient in Phase 1/2 Trial of Stem Cell Therapy for Type 1 Diabetes

 First patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 Visit -

- 91% decrease in daily insulin requirement and simultaneous robust improvements in glucose control as measured by HbA1c -

- Treatment was generally well tolerated -

https://news.vrtx.com/press-release/vertex-announces-positive-day-90-data-first-patient-phase-12-clinical-trial-dosed-vx